News
-
-
-
PRESS RELEASE
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
OSE Immunotherapeutics reports unaudited full year 2025 financial results and Q1 2026 cash position. Cash runway unchanged till early Q4 2026. Filing of 2025 Registration Document postponed to May 28, 2026 -
-
PRESS RELEASE
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
OSE Immunotherapeutics welcomes FDA Orphan Drug Designation granted to Pegrizeprument (VEL-101) for prevention of organ rejection in heart transplant patients, a novel immunomodulatory treatment developed in partnership with Veloxis Pharmaceuticals -
-
PRESS RELEASE
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
OSE Immunotherapeutics announces topline results from TEDOVA Phase 2 trial of Tedopi® in Ovarian Cancer at ASCO 2026 Meeting. Presentation by lead investigator Alexandra Leary, MD, PhD -
-
PRESS RELEASE
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
OSE Immunotherapeutics to present a novel FPR2 agonist monoclonal antibody aiming to resolve chronic inflammation at the AAI 2026 Meeting in Boston -
